Levossimendano Tillomed

Levosimendan, the active ingredient in Levossimendano Tillomed, is a calcium sensitizer presented as a sterile solution for injection for intravenous use. It improves cardiac contractility and reduces preload and afterload, and is indicated for acute decompensated heart failure in adult patients.

GNH USA supplies Levossimendano Tillomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. All batches meet EU GMP standards and are shipped under controlled conditions to ensure product integrity throughout.

Levosimendan is a calcium sensitizer used in the management of heart failure.

Acute decompensated heart failure: improves cardiac output and relieves symptoms of low output. Low‑output syndrome after cardiac surgery: supports hemodynamics when conventional therapy is insufficient. Severe chronic heart failure (palliative support): provides symptomatic benefit as a bridge to other interventions.

Levosimendan may be associated with several adverse reactions.

Common Side Effects: - Hypotension: drop in blood pressure, especially after rapid infusion. - Headache: mild to moderate intensity. - Nausea or vomiting: gastrointestinal discomfort. - Tachycardia: increased heart rate. - Dizziness: feeling of light‑headedness. - Flushing: warm sensation and reddening of skin.

Serious or Rare Side Effects: - Severe hypotension: may require vasopressor support. - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Myocardial ischemia: chest pain due to reduced coronary perfusion. - Allergic reactions: rash, pruritus, or anaphylaxis. - Pulmonary edema: fluid accumulation in lungs. - Liver enzyme elevation: abnormal hepatic function tests.

Levosimendan requires careful monitoring and specific safety measures.

Monitor blood pressure: watch for significant hypotension during and after infusion. Assess cardiac rhythm: observe for arrhythmias, especially in patients with pre‑existing conduction disorders. Use with caution in renal impairment: adjust monitoring as clearance may be reduced. Avoid in severe hepatic dysfunction: limited metabolism may increase exposure. Pregnancy and lactation: safety unknown; only use if potential benefit justifies risk. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with other cardiovascular agents, requiring attention to dosing and monitoring.

Major Interactions (Avoid): - Sodium nitroprusside: additive vasodilatory effect may cause profound hypotension. - Phosphodiesterase‑3 inhibitors (e.g., milrinone): synergistic increase in cAMP leading to excessive vasodilation. - Other potent vasodilators: risk of severe blood pressure fall.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may enhance hypotensive response. - Loop diuretics: combined effect on volume status needs observation. - Digoxin: monitor for arrhythmias as levosimendan may increase myocardial excitability. - Beta‑blockers: may blunt desired inotropic effect, requiring dose adjustments. - Anticoagulants: monitor for bleeding if hypotension leads to organ hypoperfusion.